Expand EXEL Menu
EXEL MENU

EXEL Latest Press Releases

-- April 16, 2024 --

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 Business Wire 4:05 PM

-- February 14, 2024 --

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies Globe Newswire 8:30 AM

-- February 6, 2024 --

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- February 1, 2024 --

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Business Wire 4:05 PM

-- January 25, 2024 --

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Business Wire 8:00 AM

-- January 23, 2024 --

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 Business Wire 4:05 PM

-- January 22, 2024 --

Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Business Wire 5:00 PM

-- January 18, 2024 --

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX (cabozantinib) Tablets Business Wire 4:05 PM

-- January 7, 2024 --

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 Business Wire 4:00 PM

-- January 2, 2024 --

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 Business Wire 4:05 PM

-- December 7, 2023 --

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 Business Wire 4:05 PM

-- December 4, 2023 --

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Business Wire 8:02 AM
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Business Wire 8:00 AM

-- November 29, 2023 --

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment PRNewswire 10:45 AM